Client programs using CHOMax follow platform-defined workflows and phase-appropriate practices across the development lifecycle.

New offering provides drug developers with flexible and powerful cell line development options for monoclonal antibodies, multi-specific and complex molecules SEATTLE--(BUSINESS WIRE)-- As drug ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, ...

Advances in cell line engineering and microfluidic technologies offer substantial opportunities to shorten timelines in cell line development (CLD). However, as with any innovation, optimizing these ...

U.S. government researchers have made a significant step forward in developing a fully automated process for cell-line development. The National Institute of Allergy and Infectious Diseases (NIAID), ...

This article is based on a poster originally authored by Julia Scherzinger, Daniel Türk, and Fernando Aprile-Garcia from CYTENA GmbH. There is constant pressure to reduce timelines in mammalian cell ...